5.20
-0.01(-0.19%)
Currency In USD
| Previous Close | 5.21 |
| Open | 5.09 |
| Day High | 5.26 |
| Day Low | 5.01 |
| 52-Week High | 12.32 |
| 52-Week Low | 1.94 |
| Volume | 67,968 |
| Average Volume | 2.51M |
| Market Cap | 8.1M |
| PE | -4.16 |
| EPS | -1.25 |
| Moving Average 50 Days | 4.83 |
| Moving Average 200 Days | 4.02 |
| Change | -0.01 |
If you invested $1000 in Evoke Pharma, Inc. (EVOK) 10 years ago, it would be worth $10.94 as of September 09, 2025 at a share price of $5.2. Whereas If you bought $1000 worth of Evoke Pharma, Inc. (EVOK) shares 5 years ago, it would be worth $6.89 as of September 09, 2025 at a share price of $5.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship
GlobeNewswire Inc.
Aug 26, 2025 11:00 AM GMT
Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
GlobeNewswire Inc.
Aug 21, 2025 11:00 AM GMT
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spra
Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038
GlobeNewswire Inc.
Aug 06, 2025 10:30 AM GMT
Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projectionSOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focuse